Emadine

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
10-07-2023
Karakteristik produk Karakteristik produk (SPC)
10-07-2023

Bahan aktif:

emedastine difumarate

Tersedia dari:

Immedica Pharma AB

Kode ATC:

S01GX06

INN (Nama Internasional):

emedastine

Kelompok Terapi:

Ophthalmologicals

Area terapi:

Conjunctivitis, Allergic

Indikasi Terapi:

Symptomatic treatment of seasonal allergic conjunctivitis.

Ringkasan produk:

Revision: 26

Status otorisasi:

Authorised

Tanggal Otorisasi:

1999-01-27

Selebaran informasi

                                27
B. PACKAGE LEAFLET
28
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
EMADINE 0.5 MG/ML EYE DROPS, SOLUTION
emedastine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or your pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them
even if their signs of illness are the same as yours.
-
If you get any of the side effects talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What EMADINE is and what it is used for
2.
What you need to know before you use EMADINE
3.
How to use EMADINE
4.
Possible side effects
5.
How to Store EMADINE
6.
Contents of the pack and other information
1.
WHAT EMADINE IS AND WHAT IT IS USED FOR
EMADINE IS A MEDICINE
for the treatment of seasonal allergic conjunctivitis of the eye
(allergic
conditions of the eye). It works by reducing the intensity of the
allergic reaction.
ALLERGIC CONJUNCTIVITIS.
Some materials (allergens) like pollens, house dust or animal fur may
cause
allergic reactions resulting in itching, redness as well as swelling
of the surface of your eye.
You must talk to a doctor if you do not feel better or if you feel
worse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE EMADINE
DO NOT USE EMADINE
•
IF YOU ARE ALLERGIC
to emedastine or any of the other ingredients of this medicine listed
in
section 6.
Ask your doctor for advice.
WARNING AND PRECAUTIONS
•
DO NOT USE EMADINE IN CHILDREN UNDER THE AGE OF 3 YEARS.
•
IF YOU WEAR CONTACT LENSES
please see section ‘EMADINE contains benzalkonium chloride
below’.
•
EMADINE IS NOT RECOMMENDED
for use in patients over 65 years of age, as it has not been
studied in clinical trials in this age group.
•
EMADINE IS NOT RECOMMENDED
for use in patients with kidney or liver problems.
Talk to your doctor or pharmacist bef
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
EMADINE 0.5 mg/ml, eye drops, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml of solution contains emedastine 0.5 mg (as difumarate)
Excipient with known effect
Benzalkonium chloride 0.1 mg/ml
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Eye drops, solution.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of seasonal allergic conjunctivitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
EMADINE has not been studied in clinical trials beyond six weeks.
Posology
The dose is one drop of EMADINE to be applied to the affected eye(s)
twice daily.
When used with other ophthalmic medicines, an interval of ten minutes
should be allowed between
applications of each medicinal product. Eye ointments should be
administered last.
_Elderly population _
EMADINE has not been studied in elderly patients older than 65 years,
and therefore its use is not
recommended in this population.
_Paediatric population _
EMADINE may be used in paediatric patients (3 years of age and older)
at the same posology as in
adults.
_Hepatic and Renal impairment Use _
EMADINE has not been studied in these patients and therefore, its use
is not recommended in this
population.
Method of administration
For ocular use.
3
To prevent contamination of the dropper tip and solution, care should
be taken not to touch the
eyelids, surrounding areas or other surfaces with the dropper tip of
the bottle.
After cap is removed, if tamper evident snap collar is loose, remove
before using product.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Ocular corneal infiltrates
Ocular corneal infiltrates were reported in conjunction with the use
of EMADINE. In case of corneal
infiltrates, the product should be discontinued and appropriate
management should be implemented.
Excipients
Benzalkonium chloride
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 10-07-2023
Karakteristik produk Karakteristik produk Bulgar 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 23-05-2014
Selebaran informasi Selebaran informasi Spanyol 10-07-2023
Karakteristik produk Karakteristik produk Spanyol 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 23-05-2014
Selebaran informasi Selebaran informasi Cheska 10-07-2023
Karakteristik produk Karakteristik produk Cheska 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 23-05-2014
Selebaran informasi Selebaran informasi Dansk 10-07-2023
Karakteristik produk Karakteristik produk Dansk 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 23-05-2014
Selebaran informasi Selebaran informasi Jerman 10-07-2023
Karakteristik produk Karakteristik produk Jerman 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 23-05-2014
Selebaran informasi Selebaran informasi Esti 10-07-2023
Karakteristik produk Karakteristik produk Esti 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 23-05-2014
Selebaran informasi Selebaran informasi Yunani 10-07-2023
Karakteristik produk Karakteristik produk Yunani 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 23-05-2014
Selebaran informasi Selebaran informasi Prancis 10-07-2023
Karakteristik produk Karakteristik produk Prancis 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 23-05-2014
Selebaran informasi Selebaran informasi Italia 10-07-2023
Karakteristik produk Karakteristik produk Italia 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 23-05-2014
Selebaran informasi Selebaran informasi Latvi 10-07-2023
Karakteristik produk Karakteristik produk Latvi 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 23-05-2014
Selebaran informasi Selebaran informasi Lituavi 10-07-2023
Karakteristik produk Karakteristik produk Lituavi 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 23-05-2014
Selebaran informasi Selebaran informasi Hungaria 10-07-2023
Karakteristik produk Karakteristik produk Hungaria 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 23-05-2014
Selebaran informasi Selebaran informasi Malta 10-07-2023
Karakteristik produk Karakteristik produk Malta 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 23-05-2014
Selebaran informasi Selebaran informasi Belanda 10-07-2023
Karakteristik produk Karakteristik produk Belanda 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 23-05-2014
Selebaran informasi Selebaran informasi Polski 10-07-2023
Karakteristik produk Karakteristik produk Polski 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 23-05-2014
Selebaran informasi Selebaran informasi Portugis 10-07-2023
Karakteristik produk Karakteristik produk Portugis 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 23-05-2014
Selebaran informasi Selebaran informasi Rumania 10-07-2023
Karakteristik produk Karakteristik produk Rumania 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 23-05-2014
Selebaran informasi Selebaran informasi Slovak 10-07-2023
Karakteristik produk Karakteristik produk Slovak 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 23-05-2014
Selebaran informasi Selebaran informasi Sloven 10-07-2023
Karakteristik produk Karakteristik produk Sloven 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 23-05-2014
Selebaran informasi Selebaran informasi Suomi 10-07-2023
Karakteristik produk Karakteristik produk Suomi 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 23-05-2014
Selebaran informasi Selebaran informasi Swedia 10-07-2023
Karakteristik produk Karakteristik produk Swedia 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 23-05-2014
Selebaran informasi Selebaran informasi Norwegia 10-07-2023
Karakteristik produk Karakteristik produk Norwegia 10-07-2023
Selebaran informasi Selebaran informasi Islandia 10-07-2023
Karakteristik produk Karakteristik produk Islandia 10-07-2023
Selebaran informasi Selebaran informasi Kroasia 10-07-2023
Karakteristik produk Karakteristik produk Kroasia 10-07-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 23-05-2014

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen